

Cancer Immunotherapy Guidelines

iSBTc/SITC Task Force

Purpose

- Provide evidence-based criteria for defining the clinical indications for immunotherapy.
- Provide suggestions for when and how to use immunotherapy in patients with cancer.

Process

- A multi-disciplinary team to collect and review current literature and make consensus recommendations for who, when and how immunotherapy should be used in patients with cancer.
- Develop recommendations into a manuscript.
- Make guidelines available to the public through the iSBTc/SITC web site
- Promote guidelines through other educational and promotional materials.
- Update guidelines on a regular basis.

Participants

- The participants should represent a cross section of academic and community-based physicians.
- Disease-site based.

Disease Sites for CIG

- Melanoma
- Renal Cell Carcinoma
- Other Solid Tumors (e.g. prostate cancer)
- Community physicians
- Lymphoma
- Leukemia
- Multiple myeloma
- Transplantation
- Pediatric Oncology


CIG Steering Committee

- Michael Atkins
- Steve Hodi
- Howard Kaufman
- John Kirkwood

CIG Timeline

- Establish steering committee July 2001
- Invite participants Aug-Sept 2010
- Develop prototype algorithm October 2001
- Teleconference for orientation November 2010
- Draft Guidelines submitted March 2011
- Review by task force May 2011
- Distribution to membership June 2011
- Revisions by task force August 2011
- Manuscript draft ready September 2011
- Presentation to membership October 2011

Questions?



"Notice all the computations, theoretical scribbles, and lab equipment, Norm. ... Yes, curiosity killed these cats."